RHB-104 is RedHill Biopharma’s drug candidate aimed at treating several inflammatory conditions such as Crohn’s disease, rheumatoid arthritis, and multiple sclerosis (particularly the relapsing-remitting form, RRMS). The drug is an oral capsule with potent intracellular, antimycobacterial, neuroprotective, and anti-inflammatory properties, according to RedHill.
How RHB-104 Works
Chemically, RHB-104 consists of 95 mg of clarithromycin, 45 mg of rifabutin, and 10 mg of clofazimine and is in clinical trials for treating patients with relapsing-remitting multiple sclerosis (Phase 2) and Crohn’s disease (Phase 3). The drug was initially targeted for Crohn’s disease based on evidence the disease is caused by the infection Mycobacterium avium subspecies paratuberculosis (MAP). However, the drug’s neuroprotective properties coupled with its anti-inflammatory qualities support its use in RRMS patients to combat flare-ups and remission.
A second Phase 3 trial, the MAP EU study, is in the planning stage and will be conducted in European countries simultaneously with the MAP U.S. study. Interim analysis of the MAP U.S. trial, with 270 patients, is expected toward the end of 2016, when half of the patients have completed 26 weeks of treatment.
Because bacterially induced dysfunctions of the immune system play an important part in the pathogenesis of multiple sclerosis, scientists were persuaded to undertake clinical development programs to check the drug’s effects on relapsing-remitting MS.
History of RHB-104
After acquiring RHB-104 from Sydney-based Giaconda in August 2010, RedHill put the drug through four different stages of preclinical trials, three of them featuring the murine experimental autoimmune encephalomyelitis MS model. Successful results from these trials paved the way for Phase 1 clinical trials with healthy human hosts to test the safety and toxicity of the drug.
As a result of these reports, RedHill began an 18-patient, Phase 2 proof-of-concept study of RHB-104 as an add-on therapy to Interferon Beta-1a in relapsing-remitting multiple sclerosis (CEASE-MS).
Interim results were recently announced after 24 weeks of treatment. According to RedHill, RHB-104 demonstrated positive safety and clinical signals, and the results support additional clinical development. The drug was found to be safe and well-tolerated in the trial, with no drug-related serious adverse advents.
Earlier this year, Israel-based RedHill Biopharma received a Notice of Allowance from the United States Patent and Trademark Office for its patent covering RHB-104 for Crohn’s disease.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.